Sotyktu® (deucravacitinib) has been FDA-approved for adults with active psoriatic arthritis (PsA) as of March 2026, marking a new indication for this first-in-class, oral TYK2 inhibitor.
Sotyktu targets the IL-23/TH17 and type 1 interferon pathways, providing a novel, once-daily oral option for adults living with PsA. In pivotal POETYK PsA studies, over half of participants achieved ACR50 by week 16, demonstrating meaningful improvement in joint symptoms.
This approval strengthens Sotyktu’s role as a differentiated treatment in psoriatic disease, expanding options for patients and supporting clinicians in delivering personalized care.
Contact maxim.vlasenko@globalluxrx.comSotyktu targets the IL-23/TH17 and type 1 interferon pathways, providing a novel, once-daily oral option for adults living with PsA. In pivotal POETYK PsA studies, over half of participants achieved ACR50 by week 16, demonstrating meaningful improvement in joint symptoms.
This approval strengthens Sotyktu’s role as a differentiated treatment in psoriatic disease, expanding options for patients and supporting clinicians in delivering personalized care.
